Vivek Subbiah: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally.

Quoting Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, on LinkedIn:

”Pleased to share our spotlight article in American Association for Cancer Research Cancer Discovery. Globalizing precision oncology should be a major priority for cancer care in the upcoming decades. The K-MASTER study provides a framework for infrastructure building in East Asia illustrating the widening global potential of precision oncology. It is time to modify the precision oncology mantra: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally.”

For the article click here.
Source: Vivek Subbiah/LinkedIn